Cargando…

Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation

Coronary heart disease is the main cause of mortality in patients with rheumatoid arthritis (RA), a disease known to be associated with accelerated atherosclerosis. The role of inflammation and immunity in atherosclerotic process offers possible explanations for the increased cardiovascular risk in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinelli, Francesca Romana, Pecani, Arbi, Conti, Fabrizio, Mancini, Riccardo, Alessandri, Cristiano, Valesini, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Immuno-Mediated Diseases and CV Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536531/ https://www.ncbi.nlm.nih.gov/pubmed/27683146 http://dx.doi.org/10.1177/0300060515593258

Ejemplares similares

Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case–control study
por: Erre, Gian Luca, et al.
Publicado: (2016)

Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
por: Spinelli, Francesca Romana, et al.
Publicado: (2017)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Erratum to: Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
por: Spinelli, Francesca Romana, et al.
Publicado: (2017)

Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
por: Pecani, Arbi, et al.
Publicado: (2016)

Erratum to: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
por: Pecani, Arbi, et al.
Publicado: (2016)

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab
por: Conigliaro, Paola, et al.
Publicado: (2016)

Is relative overhydration measurement by bioimpedance spectroscopy useful in reducing morbidity and mortality in chronic kidney disease?
por: Karaaslan, Doruk C, et al.
Publicado: (2018)

Relations of established aging biomarkers (IL-6, D-dimer, s-VCAM) to glomerular filtration rate and mortality in community-dwelling elderly adults
por: Stanifer, John W, et al.
Publicado: (2018)

Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study
por: Filler, Guido, et al.
Publicado: (2018)

Any grade of relative overhydration is associated with long-term mortality in patients with Stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2018)

The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis
por: Mastrangelo, Andrea, et al.
Publicado: (2015)

Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus
por: Lande, Roberto, et al.
Publicado: (2021)

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus
por: Ceccarelli, Fulvia, et al.
Publicado: (2018)

Citrullination and Carbamylation in the Pathophysiology of Rheumatoid Arthritis
por: Pruijn, Ger J. M.
Publicado: (2015)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

How the immune system responds to therapeutic biological agents
por: Vultaggio, Alessandra, et al.
Publicado: (2016)

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016)

Impact of Posttranslational Modification in Pathogenesis of Rheumatoid Arthritis: Focusing on Citrullination, Carbamylation, and Acetylation
por: Kwon, Eui-Jong, et al.
Publicado: (2021)

Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Colasanti, Tania, et al.
Publicado: (2022)

Atherosclerosis and Autoimmunity
por: Spinelli, Francesca Romana, et al.
Publicado: (2018)

Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis
por: Di Franco, Manuela, et al.
Publicado: (2018)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_apie0et47b0daill14dmemfe4r